Search for: "Takeda Global Research "
Results 1 - 20
of 39
Sort by Relevance
|
Sort by Date
30 Jan 2024, 9:31 pm
JYPIL is a peer-reviewed journal that presents trends in academic research in the field of private international law in Japan, with high-quality discussion of the most important issues in the field from both Japanese and comparative law perspectives. [read post]
26 Apr 2021, 7:42 am
Manufacturing partnerships on a global scale are cumbersome. [read post]
16 Mar 2021, 6:00 am
See, e.g., Takeda Pharm. [read post]
26 Aug 2019, 12:09 pm
Daimler: (anti-)anti suit injunctions and the Brussels I regime in global FRAND litigation | Are FRAND-disputes too complex for PI proceedings? [read post]
13 Aug 2019, 6:03 am
: Copyright and the Court of Justice of the European Union | South African IP researchers’ (AIPLITL) conference report – The IP and IT Law Innovation Interface | Event report - Second IP Researchers Europe Conference in Geneva | Why is there less innovation? [read post]
1 Dec 2017, 11:35 am
Two oncology drugs, Iclusig and Brigatinib, will enhance Takeda’s position in hematology. [read post]
30 Nov 2017, 5:47 pm
§ 355(c)(3)(C), (j)(5)(B)(iii).from Takeda, 78 F. [read post]
27 Feb 2015, 6:35 am
The company folks in Osaka, Japan will have to give serious thought to stop the hemorrhaging of money in the defense of these indefensible bladder cancer cases and go for a global settlement. [read post]
13 Feb 2015, 1:13 pm
The company folks in Osaka, Japan will have to give serious thought to stop the hemorrhaging of money in the defense of these indefensible bladder cancer cases and go for a global settlement. [read post]
9 Feb 2015, 5:41 pm
Wisniewski and other users allege that Takeda researchers ignored or downplayed concerns about the Actos bladder cancer links before it went on sale in the U.S. and misled U.S. regulators about the diabetic medication risks. [read post]
5 Apr 2014, 4:25 pm
Thousands of product liability lawsuits have been filed against Takeda Pharmaceuticals and Eli Lilly, the drug mamanufacturers for failure to research the medication and failure to provide sufficient warnings to patients and doctors. [read post]
25 Oct 2012, 9:20 pm
Consider how common a disease type 2 diabetes is—285 million are afflicted globally—and how many of these people have been prescribed Actos over the years. [read post]
15 Aug 2012, 11:02 am
(“Watson”), involves generic versions of Takeda Global Research & Development Center, Inc. [read post]
7 Jul 2012, 12:22 pm
Actos is one of Takeda’s top-selling drugs with global sales of $4.8 billion last year; in 2008, Actos was the 10th best -selling medication in the United States. [read post]
7 Jul 2012, 12:22 pm
Actos is one of Takeda’s top-selling drugs with global sales of $4.8 billion last year; in 2008, Actos was the 10th best -selling medication in the United States. [read post]
18 Jan 2012, 8:54 am
Takeda did not research the cause of increased rate of tumor formation, nor did it conduct further studies with human volunteers. [read post]
11 Jan 2012, 9:44 pm
Takeda International is a global pharmaceutical company headquartered in Japan. [read post]
8 Jan 2012, 9:05 pm
Mylan, Inc. et al. 1:12-cv-00024; filed January 3, 2011 in the Southern District of New York • Plaintiffs: Takeda Pharmaceutical Co.; Takeda Pharmaceuticals North America, Inc.; Takeda Global Research and Development Center, Inc.; Watson Pharmaceuticals, Inc.; Andrx Labs, LLC • Defendants: Mylan, Inc.; Mylan Pharmaceuticals, Inc. [read post]
17 Sep 2011, 5:43 am
The lawsuit alleges that Actos' manufacturer, Takeda Pharmaceuticals North America (and other entities including: Takeda Global Research & Development Center Inc., Takeda Pharmaceuticals Company Ltd., Takeda Pharmaceuticals America, Takeda San Diego Inc., Takeda Pharmaceuticals International Inc and Eli Lilly and Company), was negligent for not providing any warnings regarding the increased bladder cancer risk… [read post]
31 May 2011, 8:38 pm
– response to OPPI vice chairman’s interview with the Financial Express (Spicy IP) Japan: IP High Court guidance on availability of patent term extension for new forms of previously approved medicine (The SPC Blog) Japan – IP High Court offers guidance on patent term extension for combination of known drugs (The SPC Blog) Switzerland – The Swiss Federal Supreme Court approves new dosage regime as patentable subject matter in Swiss Type Claims under the EPC 1973 – Merck… [read post]
